Publications by authors named "Emel Mutlu"

Claim this Profile
P
Prognostic role of prognostic nutritional index change in patients with extensive stage small cell lung cancer treated with platinum-based chemotherapy.
İrfan Buğday, Mevlüde İnanç, Metin Özkan, Oktay Bozkurt, Ramazan Coşar, Emel Mutlu

BMC Cancer· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of cyclin-dependent kinase 4/6 inhibitors and renin-angiotensin system inhibitors in breast cancer treatment: a promising therapeutic approach.
Emel Mutlu, Mevlüde İnanç

Rev Assoc Med Bras (1992)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Investigation of the relationship between lower urinary tract symptoms, physical activity, and quality of life in overweight and obese women.
Emel Mutlu, Humeyra Kiloatar, Fatıma Yaman

Health Care Women Int· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Malnutrition on Treatment Efficacy and Toxicity in Geriatric Patients Treated With Immune Checkpoint Inhibitors.
Ilknur Deliktaş Onur, Emel Mutlu, Kadriye Başkurt, Mevlüde Inanç, Osman Sütçüoğlu

Cancer Diagn Progn· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Factors in Metastatic Urothelial Carcinoma Treated Without Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (M-VAC): A Single-Center Retrospective Study.
Irfan Bugday, Mevlude Inanc, Metin Ozkan, Oktay Bozkurt, Ramazan Cosar, Emel Mutlu

Cureus· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of elevated C-reactive protein and procalcitonin in patients with extensive-stage small cell lung cancer.
İrfan Buğday, Mevlüde İnanç, Metin Özkan, Oktay Bozkurt, Ramazan Coşar, Emel Mutlu

Anticancer Drugs· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the effectiveness of the Charlson Comorbidity Index in predicting immune checkpoint inhibitor-related adverse events.
İlknur Deliktaş Onur, Emel Mutlu, Elif Sertesen, Tuğba Önder, Ayşe Ocak Duran

Immunotherapy· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study.
Hasan Çağrı Yıldırım, Yasin Kutlu, Emel Mutlu, Musa Barış Aykan, Mustafa Korkmaz

Int J Clin Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey.
Arif Akyildiz, Deniz Can Guven, Ahmet Anil Ozluk, Rashad Ismayilov, Emel Mutlu

Medicine (Baltimore)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical outcomes of cyclin-dependent kinase 4-6 (CDK 4-6) inhibitors in patients with male breast cancer: A multicenter study.
Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, Miraç Özen, Merve Keskinkılıç

Breast· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis